Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LYPDISO™
    • LYPDISO™ Overview
    • Omega-3 Fatty Acids
  • LNC Technology
    • LNC Platform
    • MAT2203
    • MAT2501
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Sep 19, 2017 9:20am EDT

Matinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference

Sep 12, 2017 7:30am EDT

Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001

Aug 08, 2017 6:05am EDT

Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501

Aug 03, 2017 8:05am EDT

Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference

Aug 01, 2017 8:30am EDT

Matinas BioPharma to Host Quarterly Update Conference Call

Jun 26, 2017 6:05am EDT

Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis

Jun 03, 2017 4:00pm EDT

Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis

Jun 02, 2017 4:01pm EDT

Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis

Jun 01, 2017 7:05am EDT

Matinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference

May 30, 2017 8:05am EDT

Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology’s ASM Microbe 2017 Conference

RSS
  • Prev
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...19
    Next
    Matinas BioPharma Holdings, Inc.

    Science

    • LYPDISO™ (MAT9001)
    • MAT2203
    • MAT2501
    • LNC PLATFORM

    Investors

    • COMPANY PROFILE
    • STOCK DATA
    • ANALYST COVERAGE
    • GOVERNANCE
    • PRESS RELEASES
    • EVENTS
    • PRESENTATIONS
    • SEC FILINGS

    Company

    • OVERVIEW
    • OUR TEAM
    • NEWS
    • CAREERS
    • CONTACT US

    Register for updates

    Follow Us

    LinkedIn facebook twitter
    © 2021 Matinas BioPharma Holdings, Inc. All Rights Reserved.